الولايات المتحدة · منصات وبيانات · Finviz

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

نشره Finviz · الولايات المتحدة منذ 11 س

Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO ® upon close and infliximab-abda in Q3 2027; Collaboration combines Samsung Bioepis’ biosim ...

اقرأ المقال كاملًا على Finviz سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finviz.com)

يستحق القراءة أيضًا

The Motley Fool

Why Did Bloom Energy Stock Jump 10% Today?

MarketWatch

Want to help your adult kids and grandkids? Give them money while you’re still alive.

MarketBeat

Energy Vault (NRGV) Set to Post Quarterly Earnings on Tuesday

Yahoo Finance

Colorado homeowners face $7,000 to $20,700 HOA special assessments for hail-damaged roofs — or risk foreclosure

CNBC

Morgan Stanley's Ariana Salvatore on U.S. midterms: Executive policy is the story for markets

TheStreet